Earnings Call Summary | Corcept Therapeutics(CORT.US) Q1 2024 Earnings Conference
Earnings Call Summary | Corcept Therapeutics(CORT.US) Q1 2024 Earnings Conference
As of March 31, 2024, the company had cash and investments amounting to $451 million.The following is a summary of the Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Call Transcript:
以下是Corcept Therapeutics Incorporated（CORT）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Corcept Therapeutics reported Q1 2024 revenues of $146.8 million, a 39% increase compared to the same quarter of the previous year.
Company's net income increased to $27.8 million in Q1 2024 up from $15.9 million in Q1 2023.
As of March 31, 2024, the company had cash and investments amounting to $451 million.
The company has revised its revenue guidance for the year 2024 to a range of $620 million to $650 million.
Corcept Therapeutics報告稱，2024年第一季度收入爲1.468億美元，與去年同期相比增長了39％。
公司的淨收入從2023年第一季度的1,590萬美元增至2024年第一季度的2780萬美元。
截至2024年3月31日，該公司的現金和投資總額爲4.51億美元。
該公司已將其2024年的收入預期修訂爲6.2億美元至6.5億美元之間。
Business Progress:
業務進展：
Corcept has successfully completed enrollment for four trials focused on hypercortisolism, Cushing's syndrome, and cancer.
The results from the studies - GRACE, GRADIENT, CATALYST on Cushing's syndrome, ROSELLA on ovarian cancer, and DAZALS on ALS- are expected within 2024.
Despite the ongoing legal battle with Teva Pharmaceuticals, the number of new Korlym prescribers, and patients continue to grow.
Corcept is planning to file a New Drug Application (NDA) based on positive data from the GRACE study.
There's a speculative anticipation that the adrenal cancer study results, expected mid-2024, could potentially enhance the effectiveness of immunotherapy.
Corcept已成功完成四項以皮質醇增多症、庫欣綜合徵和癌症爲重點的試驗的入組。
這些研究的結果——GRACE、GRADIENT、庫欣綜合徵催化劑、卵巢癌的ROSELLA和ALS的DAZALS——預計將在2024年內公佈。
儘管與梯瓦製藥公司的法律鬥爭仍在繼續，但新的Korlym處方者和患者人數仍在持續增長。
Corcept計劃根據GRACE研究的積極數據提交新藥申請（NDA）。
有人猜測，腎上腺癌的研究結果預計將於2024年中期公佈，有可能增強免疫療法的有效性。
More details: Corcept Therapeutics IR
更多詳情： Corcept 治療公司 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。
